A simplified prognostic score for T-cell large granular lymphocyte leukaemia
AbstractBackground T-cell large granular lymphocyte leukaemia (T-LGLL) generally has a favourable prognosis, but a small proportion of patients are facing a relatively short survival time. This study aimed to identify clinical factors associated with survival in patients with T-LGLL and develop a pr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2023.2258899 |
| _version_ | 1797302159764619264 |
|---|---|
| author | Hailing Liu Jingjing Guo Lei Cao Huayuan Zhu Yi Miao Xinyi Du Yujie Wu Wei Xu Jianyong Li Lei Fan |
| author_facet | Hailing Liu Jingjing Guo Lei Cao Huayuan Zhu Yi Miao Xinyi Du Yujie Wu Wei Xu Jianyong Li Lei Fan |
| author_sort | Hailing Liu |
| collection | DOAJ |
| description | AbstractBackground T-cell large granular lymphocyte leukaemia (T-LGLL) generally has a favourable prognosis, but a small proportion of patients are facing a relatively short survival time. This study aimed to identify clinical factors associated with survival in patients with T-LGLL and develop a predictive model for guiding therapeutic decision-making.Materials and Methods We conducted a retrospective study on 120 patients with T-LGLL. Lasso regression was performed for feature selection followed by univariate and multivariate Cox regression analysis. A decision tree algorithm was employed to construct a model for predicting overall survival (OS) in T-LGLL.Results The median age of diagnosis for the entire cohort was 59 years, and 76.7% of patients reported disease-related symptoms. After a median follow-up of 75 months, the median OS was not reached. The 5-year OS rate was 82.2% and the 10-year OS rate was 63.8%. Multivariate analysis revealed that an Eastern Cooperative Oncology Group performance status over two and a platelet count below 100 × 109/L were independently associated with worse OS, leading to the development of a simplified decision tree model. The model’s performance was adequate when internally validated. The median OS of the high- and intermediate-risk- risk groups was 43 and 100 months respectively, whereas the median OS of the low-risk group was not reached. Furthermore, we found that immunosuppressive agent-based conventional treatment was unsatisfactory for our high-risk patients.Conclusions Our model is an easily applicable clinical scoring system for predicting OS in patients with T-LGLL. However, external validation is essential before implementing it widely. |
| first_indexed | 2024-03-07T23:32:51Z |
| format | Article |
| id | doaj.art-9d48c8b2f5cb44cfb626c0aa95d84f82 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-07T23:32:51Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-9d48c8b2f5cb44cfb626c0aa95d84f822024-02-20T11:58:23ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155210.1080/07853890.2023.2258899A simplified prognostic score for T-cell large granular lymphocyte leukaemiaHailing Liu0Jingjing Guo1Lei Cao2Huayuan Zhu3Yi Miao4Xinyi Du5Yujie Wu6Wei Xu7Jianyong Li8Lei Fan9Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Geriatric, Nanjing Second Hospital, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, ChinaAbstractBackground T-cell large granular lymphocyte leukaemia (T-LGLL) generally has a favourable prognosis, but a small proportion of patients are facing a relatively short survival time. This study aimed to identify clinical factors associated with survival in patients with T-LGLL and develop a predictive model for guiding therapeutic decision-making.Materials and Methods We conducted a retrospective study on 120 patients with T-LGLL. Lasso regression was performed for feature selection followed by univariate and multivariate Cox regression analysis. A decision tree algorithm was employed to construct a model for predicting overall survival (OS) in T-LGLL.Results The median age of diagnosis for the entire cohort was 59 years, and 76.7% of patients reported disease-related symptoms. After a median follow-up of 75 months, the median OS was not reached. The 5-year OS rate was 82.2% and the 10-year OS rate was 63.8%. Multivariate analysis revealed that an Eastern Cooperative Oncology Group performance status over two and a platelet count below 100 × 109/L were independently associated with worse OS, leading to the development of a simplified decision tree model. The model’s performance was adequate when internally validated. The median OS of the high- and intermediate-risk- risk groups was 43 and 100 months respectively, whereas the median OS of the low-risk group was not reached. Furthermore, we found that immunosuppressive agent-based conventional treatment was unsatisfactory for our high-risk patients.Conclusions Our model is an easily applicable clinical scoring system for predicting OS in patients with T-LGLL. However, external validation is essential before implementing it widely.https://www.tandfonline.com/doi/10.1080/07853890.2023.2258899Leukaemialymphoproliferative disordersdecision treeprognosissurvival |
| spellingShingle | Hailing Liu Jingjing Guo Lei Cao Huayuan Zhu Yi Miao Xinyi Du Yujie Wu Wei Xu Jianyong Li Lei Fan A simplified prognostic score for T-cell large granular lymphocyte leukaemia Annals of Medicine Leukaemia lymphoproliferative disorders decision tree prognosis survival |
| title | A simplified prognostic score for T-cell large granular lymphocyte leukaemia |
| title_full | A simplified prognostic score for T-cell large granular lymphocyte leukaemia |
| title_fullStr | A simplified prognostic score for T-cell large granular lymphocyte leukaemia |
| title_full_unstemmed | A simplified prognostic score for T-cell large granular lymphocyte leukaemia |
| title_short | A simplified prognostic score for T-cell large granular lymphocyte leukaemia |
| title_sort | simplified prognostic score for t cell large granular lymphocyte leukaemia |
| topic | Leukaemia lymphoproliferative disorders decision tree prognosis survival |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2023.2258899 |
| work_keys_str_mv | AT hailingliu asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT jingjingguo asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT leicao asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT huayuanzhu asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT yimiao asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT xinyidu asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT yujiewu asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT weixu asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT jianyongli asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT leifan asimplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT hailingliu simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT jingjingguo simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT leicao simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT huayuanzhu simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT yimiao simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT xinyidu simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT yujiewu simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT weixu simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT jianyongli simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia AT leifan simplifiedprognosticscorefortcelllargegranularlymphocyteleukaemia |